The document outlines the 'Young and Strong' program, initiated in 2005 to support young women diagnosed with breast cancer, addressing their unique needs in areas such as fertility, psychosocial health, and treatment. It details ongoing research studies like the Young Women's Breast Cancer Study, involving over 1,300 participants, focusing on various aspects of breast cancer outcomes and health-related quality of life. Additionally, it highlights ongoing projects aimed at improving survivorship through mindfulness interventions and evaluations of treatment interruptions for pregnancy.

1. Research in the Program for Young
Women with Breast Cancer:
Past, Present and Future
Shoshana Rosenberg, ScD and
Ann H. Partridge, MD MPH
Dana-Farber Cancer Institute
January 24, 2018

2. • In 2005, we established The Program for Young Women
with Breast Cancer (“Young and Strong”) to address the
unique issues facing the young patients at DFCI
• The program addresses critical issues including:
 Fertility
 Genetics
 Parenting
 Sexual functioning
 Psychosocial and Emotional Health
 Exercise and Nutrition
 Balancing School and/or a Career
 Building Relationships
• Initially, the program served women diagnosed at age
42 and younger but include women up to 45 now
• To date: directly served over 4,000 new young patients
visiting our breast oncology clinics

3. A Comprehensive and Integrated Program
Focused on Young Women
Clinical Care
Research
Education
(both patient and provider)

4. Local therapy
Genetics
Endocrine
therapy
Chemotherapy
Fertility
Adherence
Psychosocial
functioning
Sexual health
Young age

5. Helping Ourselves, Helping Others:
The Young Women’s Breast Cancer Study (YWS)
Prospective cohort established in 2006
• Women age ≤40 at diagnosis of breast cancer
• Eastern Massachusetts, Colorado, MN, Canada
Outcomes
• Disease, tumor biology/molecular characteristics
• Treatment issues (surgical decisions, adherence)
• Psycho-social (fertility, sexuality, workplace issues)
• Lifestyle factors (alcohol, exercise, weight gain)
• Health services (delay in diagnosis, survivorship care)
Accrual
• 1302 participants enrolled
• Surveys: every 6 months x 3 years, annually thereafter
• Blood: 91% of patients with at least one sample
• Tumor: 98% consented, centrally reviewed by study pathologists,
block banked for future research
PI: Partridge
Co-PI: Rosenberg

6. Participating Sites
o Brigham and Women’s Hospital/DFCI
o Faulkner Hospital
o Massachusetts General Hospital
o Beth Israel Deaconess Medical Center
o South Shore Hospital
o Mass General/North Shore Cancer Center
o Cape Cod Healthcare
o Lowell General Hospital
o Newton Wellesley Hospital
o Sunnybrook Health Sciences Center
o University of Colorado – Denver
o Mayo Clinic
o Also, related studies on-going in Europe, Saudi Arabia, Israel

7. Recruitment
• Inclusion Criteria
• Female
• New diagnosis of breast cancer (no history of breast cancer)
• Stage 0-4 included but exclude pure LCIS
• Age 40 or younger at diagnosis
• Informed consent obtained from patient
• Ability to understand written and spoken English to the extent necessary to complete
the questionnaires
• At Partners institutions, potentially eligible cases were identified from review of tumor
registry lists
• At some sites, research nurses and/or research coordinators assisted with recruitment
via review of patient lists

8. Study/Survey timeline
All surveys are sent based on patients’date of
diagnosis, except the baseline and 6 month surveys
Consent
Survey 1
Blood
sample
Survey 2 Survey 3
Blood
sample
Survey 4
Med Rec
Request
Tissue
Request
Survey 5 Survey 6
3 year 20 year =
annual surveys
4 year = final blood
sample
7, 10 year = LTF Re-
engagement
Baseline 6 mos 1 yr 18 mos 2 yrs 30 mos 3 20 yrs

9. Some examples of survey measures
• Socio-demographics
• Medical and family history
• Genetics
• Fertility issues and outcomes
• General quality of life
• Anxiety and depression
• Menopausal symptoms
• Physical activity

10. Timepoint Range
Baseline Enrollment – 9 months post diagnosis
1 Year 9 months – 2 years post diagnosis
4 year 3.5 years – 5 years post diagnosis
Blood Specimen Collection
• We work with coordinators at participating sites to arrange these draws or we
send blood kits directly to the patients with appointments offsite
• We process these specimens and isolate whole blood + plasma before freezing
them for future studies
• 1224/1302 =94% women have consented to blood
• Of these, >90% have contributed at least one sample

11. Tissue Specimen Collection
• We collect specimens to characterize the
tumors and bank for future studies
utilizing:
• molecular evaluations of disease
characteristics (via TMA)
• genetic variability (via whole exome
sequencing)
• 1278/1302=98% have consented to
pathology specimen collection
• Of these, >80% have undergone
pathology review

12. Overview of selected completed/
Ongoing studies
• Pathologic features and biology of breast cancer in
young women
• Health care delivery
• Local therapy and patient decision making
• Fertility and pregnancy issues
• Psycho-social and quality of life issues

13. Pathologic features/molecular phenotype
• Pathologic features and molecular phenotype by
patient age in a large cohort of young women with
breast cancer
• Molecular Phenotype of Breast Cancer According to
Time Since Last Pregnancy in a Large Cohort of
Young Women

14. Collins et al. BCRT 2012
• N=399 women
• No differences in clinico-pathologic phenotype by age
• 35% were luminal B

15. Collins et al. The Oncologist 2015
• N=707 women
• No association with parity or recency of pregnancy and
molecular phenotype, adjusting for age at diagnosis and family
history

16. Health care delivery
• Breast cancer presentation and diagnostic delays in
young women
• BRCA1 and BRCA2 mutation testing in young
women with breast cancer

17. Ruddy et al. Cancer 2014

18. Rosenberg et al. JAMA Onc 2016

19. • Perceptions, knowledge, and satisfaction with
contralateral prophylactic mastectomy among
young women with breast cancer: a cross-sectional
survey
• Local therapy decision-making and contralateral
prophylactic mastectomy in young women with
early-stage breast cancer
Local therapy

20. • 123 women with unilateral breast cancer, age 40 or
younger at diagnosis who had undergone bilateral
mastectomy
• ~25% BRCA 1 or BRCA 2 mutation carriers
• Median time since surgery: 2.1 (range: 0.1-4.3)
years
• Median age at diagnosis: 37 (26-40) years
• 79% Stage I/II at diagnosis

21. Rosenberg et al. Ann Intern Med 2013
Reasonsfor choosingCPM

22. • 560 women with Stage I-III unilateral breast cancer
enrolled in YWS
• Characterization of decision-making process,
including involvement and confidence with the
decision
• Assessment of socio-demographic, clinical and
decisional factors associated with CPM vs. breast
conserving surgery and unilateral mastectomy

23. Decisional involvement
Rosenberg et al. Ann Surg Onc 2015

24. Local therapy decision-making and CPM in
young women with early-stage breast cancer
Rosenberg et al. Ann Surg Onc 2015
• Among women where BCS was an option or was
recommended, choosing CPM (vs. other types of
surgery) was associated with:
• Testing positive for a BRCA mutation
• Higher levels of generalized anxiety
• Lower BMI
• Lower levels of fear of recurrence

25. Fertility is a primary issue
Ruddy et al, J Clin Oncol, 2014

26. Enrolled in YWS, n=1302
Completed abbreviated
surveys, n=137
No baseline survey,
n=89
YWS: fertility outcomes
Analytic cohort, n=1076

27. Patient, disease, treatment characteristics
Characteristic Patients (n=1076)
Age at diagnosis n (%)
≤30 years (yr) 140 (13)
31-35 years 293 (27)
36 – 40 years 643 (60)
Stage
0 88 (8)
I 355 (33)
II 422 (40)
III 145 (14)
IV 56 (5)
Partnered at diagnosis
Yes 806 (75)
No 263 (25)
Children prior to diagnosis
Yes 691 (64)
No 385 (36)
Phenotype
ER+ 772 (72)
ER- 293 (28)
Adjuvant endocrine therapy
Yes 704 (65)
No 372 (35)
Chemotherapy
Yes 802 (75)
No 270 (25)
Median follow-up:
5 years

28. 38%
26% 27%
24% 24%
20%
15% 14% 13%
11%
7% 7%
0%
10%
20%
30%
40%
50%
Interest in future biologic children
n=1076

29. Fertility preservation use
79
29
1
34
1
10
0
10
20
30
40
50
60
70
80
90
Embryo
cryopreservation
Oocyte
cryopreservation
Ovarian tissue
cryopreseration
GnRH agonist OCPs Other
Numberofpatients
* 133/1206 (11%) patients took steps to
preserve fertility prior to treatment
OCPs=oral contraceptive pills

30. 87%
70%
64%
13%
30%
36%
0%
20%
40%
60%
80%
100%
≤30 years 31-35 years 36 – 40 years
No TRA
TRA
No amenorrhea
Amenorrhea
100%
60%
0%
40%
0%
20%
40%
60%
80%
100%
No chemotherapy Chemotherapy
No TRA
TRA
No amenorrhea
Amenorrhea
n=69 n=128 n=310 n=111 n=396
76%
64%
24%
36%
0%
20%
40%
60%
80%
No tamoxifen Tamoxifen
No TRA
TRA
No amenorrhea
Amenorrhea
n=188 n=319
Amenorrhea varies by age and use of
chemotherapy and tamoxifen
Poorvu et al, ASCO, 2015

31. Total cohort,
n=1076
Interested,
n= 387 (36%)
Not interested,
n= 689 (64%)
Cumulative pregnancy interest, attempts,
and outcomes
 Excluded pregnancies occurring
at time of diagnosis

32. Total cohort,
n=1076
Attempted,
n= 138 (36%)
Interested,
n= 387 (36%)
No attempt,
n= 249 (64%)
Not interested,
n= 689 (64%)
Attempted,
n= 8 (1%)
No attempt,
n= 681 (99%)
Cumulative pregnancy interest, attempts,
and outcomes
 Excluded pregnancies occurring
at time of diagnosis

33. Total cohort,
n=1076
Attempted,
n= 138 (36%)
Interested,
n= 387 (36%) Pregnant,
n= 13 (5%)
Not pregnant,
n= 236 (95%)
No attempt,
n= 249 (64%)
Pregnant,
n= 1 (13%)
Not pregnant,
n= 7 (87%)Not interested,
n= 689 (64%)
Pregnant,
n= 9 (1%)
Not pregnant,
n= 672 (99%)
Pregnant,
n= 94 (68%)
Not pregnant,
n= 44 (32%)
Attempted,
n= 8 (1%)
No attempt,
n= 681 (99%)
Cumulative pregnancy interest, attempts,
and outcomes
 Excluded pregnancies occurring
at time of diagnosis

34. Total cohort,
n=1076
Attempted,
n= 138 (36%)
Interested,
n= 387 (36%) Pregnant,
n= 13 (5%)
Not pregnant,
n= 236 (95%)
No attempt,
n= 249 (64%)
Pregnant,
n= 1 (13%)
Not pregnant,
n= 7 (87%)Not interested,
n= 689 (64%)
Pregnant,
n= 9 (1%)
Not pregnant,
n= 672 (99%)
Pregnant,
n= 94 (68%)
Not pregnant,
n= 44 (32%)
Attempted,
n= 8 (1%)
No attempt,
n= 681 (99%)
Cumulative pregnancy interest, attempts,
and outcomes
 Excluded pregnancies occurring
at time of diagnosis

35. Live births, 108,
61%
Micarriages, 44,
25%
Abortions, 7, 4%
Stillbirths, 2, 1%
TBD, 15,
9% 173 pregnancies
among 117 women
(including 3 sets of
twins)
Median f/u: 5 years
Pregnancy outcomes

36. Psycho-social and Quality of Life
• Body image
• Body image in recently diagnosed young women with early
breast cancer
• Sexual functioning
• Treatment-related amenorrhea and sexual functioning in
young breast cancer survivors
• Anxiety/Depression
• Partner support and anxiety in young women with breast
cancer
• Depression and anxiety symptoms in young women with
metastatic disease

37. • Local therapy and QOL
• Breast-Q (Dominici/Rosenberg)
• Longitudinal analysis of QOL outcomes by surgery type
(Rosenberg)
• Adjuvant systemic therapy
• Endocrine therapy adherence (Wassermann)
• Endocrine therapy initiation and persistence (Rosenberg)
• Psychosocial
• Post-traumatic stress disorder (Vazquez, HMS)
• Trajectories in sexual function (von Hippel, HSPH)
• Experience of partners of young women with breast cancer
(Borstelmann)
Ongoing projects

38. Partner sub-study
• One-time cross-sectional survey of partners of cohort
participants
• Outcomes included social support, quality of life,
coping, parenting concerns, anxiety, depression, post-
traumatic growth, sexual satisfaction
• N=332 respondents
• Almost all respondents were male
• In women not in “active treatment,” median follow-up from
(patient) diagnosis to survey of partner was 58 months

39. Concern N (%) Missing N
Anxiety (HADS subscore ≥8) 106 (42) 39
Depression (HADS subscore ≥8) 47 (21) 60
Parenting concerns (N=208 with children) 74 (36) 4
Relationship strain 89 (32) 12
Financial insecurity 79 (29) 17
Not sexually active 55 (20) 12
Maladaptive coping style 120 (44) 19
Social support (MOS-SS summary score) Median
(range)
67 (19-95)
15
Table 2. Prevalence of psychosocial concerns in partners (N=289)
Abbreviations: HADS, Hospital Anxiety and Depression Scale; MOS-SS, Medical Outcomes
Survey-Social Support Survey
• Many partners of breast cancer survivors experience substantial psychosocial
distress
• In an analysis of factors associated with anxiety, maladaptive coping during
treatment was associated with higher levels of anxiety
• Attention to the psycho-social health of caregivers is critical during both the
treatment and survivorship phases of care

40. • Biology
• Understanding the genomic underpinnings of breast
cancer in young women (Wagle)
• ctDNA to identify MRD and risk of recurrence in young
women (Parsons)
• Whole Exome Sequencing of Treatment Resistant HER2+
Breast Cancer (Wagle/Waks)
• Whole Exome Sequencing of Triple Negative Breast
Cancer (Stover)
Ongoing projects

42. PATHWAYS TO WELLNESS STUDY
Improving Outcomes for Younger Breast Cancer Survivors: A randomized trial comparing
outcomes for women receiving a mindfulness awareness practice group intervention, a
health education curriculum tailored to younger women, or a delayed intervention control
condition PIs: Ganz
and Bower
• Based on successful randomized pilot data from a single
site pilot randomized trial at UCLA
• 3 arm, multi-center RCT evaluating mindfulness vs. ed. vs.
control
• 6 week intervention teaching mindfulness awareness
practices (MAPs)
• Sitting and walking meditations
• Application to physical symptoms, emotions, and
thoughts
• Focus on relevance for cancer survivorship

43. Study Outcomes: Post-treatment
• Psychological:
• Perceived stress, depression, anxiety
• Symptoms:
• Fatigue, sleep, pain
• Health behaviors:
• Stress-related eating, physical activity
• Biological:
• Inflammation, insulin, glucose
• Heart rate variability
• Reactivity to challenge

44. Pregnancy Outcome and Safety of Interrupting Therapy
for women with endocrine responsIVE Breast Cancer
IBCSG 48-14 / BIG 8-13
ALLIANCE # A221405
POSITIVE TRIAL
INTERNATIONAL PI: OLIVIA PAGANI
NORTH AMERICAN PI: ANN PARTRIDGE

45. The POSITIVE Trial: Endocrine therapy interruption for
pregnancy in breast cancer patients
• Phase II trial designed to evaluate safety and
pregnancy outcomes of interrupting ET for young
women with ER+ disease who desire pregnancy
• Enroll 512 women, <42, premenopausal, have
completed between 18-30 months of ET
• Study participants come off endocrine therapy for
up to 2 years for a pregnancy attempt, restart
hormonal therapy
• Outcomes: disease, reproductive, psychosocial

46. YWS2: from observation to intervention
Diagnosis Treatment Long-term
Survivorship
Enrollment
Surgical DA
Mindfulness
intervention
Symptom management to
improve ET adherence
6 mo 12 mo
Addressing menopausal
sx, sexual dysfunction
Expanding TS/SCP+
research pilot

47. Thank you!
DFCI/YWS Team
Ann Partridge, PI
Shoshana Rosenberg, co-PI
Eric Winer
Rulla Tamimi
Laura Collins
Katie Ruddy
Judy Garber
Nick Wagle
Lidia Schapira
Jeff Peppercorn
Elana Brachtel
Steve Come
Ginger Borges
Ellen Warner
Shari Gelber
Phil Poorvu
The Program for Young Women Team
Kim Sprunck-Harrild
Craig Snow
Allison Higgins
Rachel Gaither
Sarah Walsh
Eric Brosnan
Megan Meyer
Sonja Darai
Stephanie Cram
Sylvia Ilahuka

48. Thank you!
CDC-DP 14-408

49. Thank you!
All of the advocates, patients, and partners
who have given their time and participated
in our research

50. QUESTIONS?